MET and prostate neoplasm: Accordingly, to dissect the net effect of c-Met suppression in the stromal compartment alone, we performed preclinical studies using cabozantinib-resistant bone metastatic prostate tumor cells, as well as in vitro studies using c-Met knockdown osteoblasts, and found that the suppression of c-Met specifically in osteoblasts suppressed osteoclastogenesis, tumor-induced osteolysis, and tumor growth in bone [20].